Table 1 Characteristics of included studies on influenza vaccine effectiveness in patients with end-stage renal disease
Author, country [Ref] | Study design, year | Age in years | Male patients (%) | Years on dialysis | Patients on hemodialysis (%) | Diagnosis of renal disease, identification of patients | Predominantly circulating influenza strains | Study size |
|---|---|---|---|---|---|---|---|---|
(mean ± SD or range) | (mean ± SD or range) | |||||||
Bond et al., US [25] | Cohort, 2005–2006 | vacc.: 60.6 ± 15.2 | vacc.: 50.8 | vacc.: 4.5 ± 3 .6 | vacc.: 92.6 | USRDS; ICD-9-CM codes | Not reported | vacc.: n = 14,226 |
unvacc.: 57.9 ± 15.9 | unvacc.: 52.5 | unvacc.: 4.8 ± 4.1 | unvacc.: 90.4 | unvacc.: n = 5,994 | ||||
Gilbertson et al., US [24]1 | Cohort, 1997–1999 | vacc.: 40–64: 36.3%; 65+: 53.8% | vacc.: 40.3 | Proportion > 4 yrs on dialysis: | 01 | USRDS; ICD-9-CM codes1 | Not reported | Patients on peritoneal dialysis: n = 13,091 |
unvacc.: 40–64: 64.7%; 65+: 46.2% | unvacc.: 59.7 | vacc: 35.9% | ||||||
unvacc.: 37.7% | ||||||||
McGrath et al., US [26] | Cohort, 1997–1999, 2001 | vacc.: 62.3–63.92 | vacc.: 52.2-53.02 | Proportion > 4 yrs on dialysis: | 100 | USRDS; ICD-9-CM codes | H3N2 (all seasons) | vacc.: n = 52,287–61,8002 |
unvacc.: 60.3–61.72 | unvacc.: 50.4-51.62 | vacc.: 29.2-30.9%2 | unvacc.: n = 55,178–64,8992 | |||||
unvacc.: 32.5-34.1%2 | ||||||||
Slinin et al., US [27] | Cohort, 1993–1994 | all: 60.3 | all: 51.1 | Proportion < 5 yrs on dialysis: | 100 | USRDS; ICD-9-CM codes | Not reported | all: n = 10,635 |
all: 75.8% | ||||||||
Wang et al., Taiwan [23] | Cohort, 1998–2009 | vacc.: 70.2 ± 9.96 | vacc.: 50.3 | Patients with “newly diagnosed” ESRD | 100 | Universal insurance data, National Health Insurance program | Not reported | vacc.: n = 831 unvacc.: n = 3,187 |
unvacc.: 59.4 ± 14.5 | unvacc.: 48.7 | |||||||
Total study population | Total: n = 174,6633 | |||||||